Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

S.S. Lund*, L. Tarnow, C.D.A. Stehouwer, C.G. Schalkwijk, T. Teerlink, J. Gram, K. Winther, M. Frandsen, U.M. Smidt, O. Pedersen, H.H. Parving, A.A. Vaag

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

INIS

Biochemistry, Genetics and Molecular Biology